Gilead Sciences, Inc. (NASDAQ: GILD), a research-based biopharmaceutical company, is focused on discovering, developing, and commercializing novel medicines to address unmet medical needs. The company’s aim is to improve the care of patients suffering from life-threatening diseases with every new discovery and experimental drug candidate. Primary areas of focus include: antivirals, cardiovascular conditions and respiratory diseases. For further information, visit the Company’s web site at www.gilead.com.
- 17 years ago
QualityStocks
Gilead Sciences, Inc. (NASDAQ: GILD)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Adjourns Special Meeting Due to Lack of Quorum
TransCode Therapeutics (NASDAQ: RNAZ) announced that its April 21 special meeting has been adjourned to…
-
Soligenix Inc. (NASDAQ: SNGX) HyBryte(TM) Paves Way for Breakthrough Treatment for Rare Skin Cancer
The global rare disease treatment market was estimated at $195.2 billion in 2024 and is…
-
Nicola Mining Inc. (TSX.V: NIM) (OTCQB: HUSIF) Is ‘One to Watch’
High-Grade Copper Opportunity: 100% ownership of the New Craigmont Project, one of British Columbia’s most promising…